Zhou Xiaonan, Liu Gang, Lai Hao, Wang Chunsheng, Li Jun, Zhu Kai
Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, 200032 Shanghai, China.
Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 200032 Shanghai, China.
Rev Cardiovasc Med. 2022 Sep 13;23(9):307. doi: 10.31083/j.rcm2309307. eCollection 2022 Sep.
Aortic aneurysms are life-threatening vascular diseases associated with high morbidity, and usually require prophylactic surgical intervention. Current preventative management of aortic aneurysms relies on the diameter and other anatomic parameters of the aorta, but these have been demonstrated to be insufficient predictive factors of disease progression and potential complications. Studies on pathophysiology of aortic aneurysms could fill this need, which already indicated the significance of specific molecules in aortic aneurysms. These molecules provide more accurate prediction, and they also serve as therapeutic targets, some of which are in preclinical stage. In this review, we summarized the inadequacies and achievements of current clinical prediction standards, discussed the molecular targets in prediction and treatment, and especially emphasized the molecules that have shown potentials in early diagnosis, accurate risk assessment and target treatment of aortic aneurysm at early stage.
主动脉瘤是一种与高发病率相关的危及生命的血管疾病,通常需要预防性手术干预。目前主动脉瘤的预防性管理依赖于主动脉的直径和其他解剖参数,但这些已被证明是疾病进展和潜在并发症的不足预测因素。对主动脉瘤病理生理学的研究可以满足这一需求,其已经表明了特定分子在主动脉瘤中的重要性。这些分子提供了更准确的预测,并且它们还可作为治疗靶点,其中一些正处于临床前阶段。在本综述中,我们总结了当前临床预测标准的不足与成就,讨论了预测和治疗中的分子靶点,并特别强调了在主动脉瘤早期诊断、准确风险评估和靶向治疗中已显示出潜力的分子。